Mounir Ghali, MD
Pulmonary Disease · Wyoming, MINPI 1205142932
Payments from drug & device makers
What this record shows
This record is dominated by education: $264,500 of the $371,126 with a category attached, or 71.3%. Intuitive Surgical accounts for 99.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $126,128 and has fallen 78.9% since, to $26,601 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $853.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$369K
- Olympus Corporation Of The Americas$1K
- Pulmonx Corporation$289
- Medical Device Business Services, Inc.$124
- Veran Medical Technologies, Inc.$76
- Bard Peripheral Vascular, Inc.$33
What the payments were for
- Speaking & faculty fees$25,5007%
- Travel & lodging$63,53217%
- Food & beverage$17,5375%
- Education$264,50071%
- Gifts$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 419 | $369,440 |
| Olympus Corporation Of The Americas | 11 | $1,164 |
| Pulmonx Corporation | 2 | $289 |
| Medical Device Business Services, Inc. | 1 | $124 |
| Veran Medical Technologies, Inc. | 1 | $76 |
| Bard Peripheral Vascular, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$371,126 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $79,007 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $3,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,929 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,796 |
| MethotrexateMethotrexate Sodium | 15 | $266 |
| Fluticasone Propionate | 16 | $201 |
| Montelukast Sodium | 11 | $171 |
| Azithromycin | 16 | $101 |
| Prednisone | 35 | $65 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Wyoming
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
- Ihab DeebajahGarden City$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.